Interaction entre Alfuzosine et Vardénafil

Caution is advised for concomitant use of PDE5-inhibitors and UROXATRAL, as this combination can potentially cause symptomatic hypotension [see Drug Interactions (7.4) ].

Concomitant use of PDE5 inhibitors with alpha adrenergic antagonists, including UROXATRAL, can potentially cause symptomatic hypotension ( 5.4 , 7.4 )

PDE5 Inhibitors Caution is advised when alpha adrenergic antagonists, including UROXATRAL, are co-administered with PDE5 inhibitors.

Phosphodiesterase-5 (PDE5) Inhibitors: PDE5-inhibitors are also vasodilators.

Alpha adrenergic antagonists and PDE5 inhibitors are both vasodilators that can lower blood pressure.

Clinical pharmacology studies have been conducted with co-administration of vardenafil with alfuzosin, terazosin or tamsulosin. [See Dosage and Administration (2.4) , Warnings and Precautions (5.6) , and Clinical Pharmacology (12.2) .] Antihypertensives: Vardenafil hydrochloride tablets may add to the blood pressure lowering effects of antihypertensive agents.

Alpha-Blockers : Caution is advised when PDE5 inhibitors are co-administered with alpha-blockers.

Alpha-Blockers Caution is advised when PDE5 inhibitors are co-administered with alpha-blockers.

Consideration should be given to the following: Patients should be stable on alpha-blocker therapy prior to initiating a PDE5 inhibitor.

Patients who demonstrate hemodynamic instability on alpha-blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of PDE5 inhibitors.